Seattle Genetics

Seattle Genetics is a pharmaceutical company which focuses on developing monoclonal antibody based treatments for use against cancer. The companys' significant product candidate is ADCETRIS (Brentuximab vedotin) which has been approved by the United States Food and Drug Administration (FDA) for two treatments; firstly, the treatment of patients with Hodgkin lymphoma after treatment failure using autologous stem cell transplant and secondly for use in the treatment of patients with systemic anaplastic large cell lymphoma.

Company history

2009

19 February — pivotal trial for Brentuximab vedotin for Hodgkin lymphoma^[1]

18 June — phase II trial of Brentuximab vedotin for Anaplastic large cell lymphoma^[2]

24 July — initiation of re-treatment clinical trial of Brentuximab vedotin^[3]

10 August — milestone achievement in collaboration with MedImmune through initiration of phase I clinical trial of MEDI-547.^[4]

8 September — milestone achievement in collaboration with Bayer for the submission of investigational new drug application with the FDA^[5]

5 October — discontinuation of Dazcetuzumab phase IIb clinical trial for the treatment of diffuse Large B-cell lymphoma^[6]

16 November — initiation of phase I clinical trial for SGN-75^[7]

11 December — termination of collaboration with Genentech for SGN-40^[8]

21 December — announcement of new collaboration with GlaxoSmithKline ($12 million up front payment, up to $390 million in milestone payments)^[9]

2010

2 February — initiation of phase I combination clinical trial of Brentuximab vedotin (SGN-35) for Hodgkin Lymphoma^[10]

3 March — milestone achievement under collaboration with Genentech^[11]

8 April — initiation of phase III trial for Brentuximab vedotin (SGN-35) for post transplant Hodgkin Lymphoma^[12]

20 April — $9.5 million payment from Genentech to extend collaboration^[13]

20 July — initiation of phase I clinical trial of ASG-5ME for treatment of Pancreatic cancer^[14]

3 August — expansion of collaboration with Genentech ($12 million ufront payment, up to $900 million in potential fees and milestone payments)^[15]

2 September — milestone achievement in collabortaion with Agensys for initiation of phase I trial of AGS-16M8F^[16]

14 September — entry into collaboration with Genmab^[17]

20 October — initiation of phase I clinical tria; of ASG-5ME in prostate cancer treatment^[18]

2011

6 January — entry into collaboration with Pfizer ($8 million upfront payment, $200+ million in potential milestone payments)^[19]

1 March — initiation of phase I clinical trial of Brentuximab vedotin for use in conjunction with chemotrherapy for treatment of systemic anaplastic large cell lymphoma^[20]

15 March — expansion of collaboration with the Millennium Pharmaceuticals (Takeda Oncology)^[21]

22 March — announcement of collaboration with Abbott ($8 million upfront payment, plus potential royalties and milestone payments)^[22]

19 April — expansion of collaboration with Genmab^[23]

19 August accelerated FDA approval for Brentuximab vedotin for use in treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma (ALCL)^[24]

23 August — initiation of phase II trial of ADCETRIS in CD30-positive Non-Hodgkin Lymphoma^[25]

9 September — collaboration with Oxford BioTherapeutics^[26]

25 October — initiation of phase II clinical trial of ADCETRIS in CD30-positive non-Lymphoma malignancies^[27]

2012

5 July — initiation of global phase III trial of ADCETRIS against CD30-expressing cutaneous T-cell lymphoma^[28]

24 August — initiation of phase Ib trial of SGN-75 for use in combination with Everolimus in patients with renal cell carcinoma^[29]

9 October — milestone achievement under collaboration with Genentech by advancements of two anti-body conjugates into phase II trials^[30]

17 October — initiation of phase II trial of ADCETRIS in age 60+ Hodgkin Lymphoma patients^[31]

23 October — expansion of collaboration with Abbott (upront payment of $25 million, milestone payment up to $220 million)^[32]

1 November — initiation of global phase III trial of ADCETRIS in untreated advanced hodgkin lymphoma patients^[33]

26 November — received Orphan drug designation for ADCETRIS treatment of mycosis fungoides^[34]

2013

1 February — Health Canada approves ADCETRIS for treatment of relapsed refractory Hodgkin lymphoma^[35]

6 February — initiation of two phase I trials of SGN-CD19A^[36]

25 June — new collaboration with Bayer^[37]

15 July — initiation of phase I trial of SGN-CD33A in treatment of Acute Myeloid Leukemia (AML)^[38]

15 August — initiation of phase II trial of ADCETRIS for diffuse Large B-cell Lymphoma^[39]

21 October — initiation of phase I trial of SGN-LIV1A for patients with LIV-1-positive metatstatic Breast cancer^[40]

Product portfolio & pipeline

ADCETRIS – used in the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

SGN-75 – used in phase 1 trial of relapsed or refractory renal cell carcinoma patients or non-Hodgkin lymphoma patients.

ASG-5ME – product candidate for the treatment of solid tumours (targets SLC44A4 in pancreatic, prostate and gastric cancer).

ASG-22ME – product candidate for the treatment of solid tumours (targets Nectin-4 in bladder, breast, lung and pancreatic cancer).

SGN-CD19A – product candidate for the treatment of hematologic malignancies

References